A study in Nature Communications reported that next-generation sequencing approaches can detect residual disease in T-cell acute lymphoblastic leukemia, addressing a key need for sensitive measurable residual disease (MRD) tracking in a fast-moving hematologic cancer category. The work highlights the value of molecular surveillance for risk stratification and monitoring after therapy. Separately, a global workflow approach was described for converting frozen tumor tissues from multiple countries into reliable whole-genome data, aiming to standardize processing in international cancer genomics efforts. Centralizing sample-to-data workflows is often a prerequisite for cross-study comparability and downstream biomarker development. Both advances are geared toward improving signal quality—MRD resolution for patients and data fidelity for researchers—supporting more consistent clinical decision-making and translational discovery.